Cost-Benefit Of Early Access To NSCLC Drugs Evaluated In JAMA Study
Researchers from University of California and Novartis present a framework for evaluating the social benefits of early access to new treatments on the basis of progression-free survival.
You may also be interested in...
Despite the agency’s preference that confirmatory trials generally be under way at the time of accelerated approval, Novartis’ panobinostat Phase III trial isn’t expected to begin for approximately three years.
FDA grants accelerated approval to ceritinib following a four-month review. The ALK inhibitor is indicated for non-small cell lung cancer patients who have progressed on or are intolerant of Pfizer’s Xalkori.
John Crowley will take the reins at BIO in March, about a year and a half after the departure of former CEO Michelle McMurry-Heath was announced.